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PSYCHOSOCIAL ADJUSTMENT IN LONG TERM SURVIVORS OF ALLOGE-
NEIC HSCT: A COMPARISON OF PATIENTS TREATED WITH MYELOABLA-
TIVE (MC) AND REDUCED INTENSITY CONDITIONING (RIC) REGIMENS
Bevans, M.1, Mitchell, S.1, Wehrlen, L.1, Prachenko, O.1, Soeken, K.2,
Koklanaris, E.1, Cook, L.1, Odom, J.1, Prince, P.1, Le, Q.1, Castro, K.1,
Cusack, G.1, Savani, B.3, Fowler, D.1, Childs, R.1, Barrett, A.J.1 1Na-
tional Institutes of Health, Bethesda, MD; 2 Independent Consultant,
Ellicott City, MD; 3Vanderbilt University, Nashville, TN
Background: Long term survivors of allogeneic HSCT (aHSCT)
may experience significant psychosocial distress. Although factors
predicting increased distress have been reported, the influence of
conditioning intensity has not been explored.
Purpose: This analysis compares the psychosocial (PS) adjust-
ment of long term survivors who received RIC (n 5 43) or MC (n
5 77) regimens and examines predictors of PS adjustment and its re-
lationship with health-related quality of life (HRQL).
Methods: Cross-sectional data were drawn from an ongoing lon-
gitudinal study. Measures included the Psychosocial Adjustment to
Illness Scale (PAIS), the Rotterdam Symptom Checklist-physical
(RSCL-P) and the Functional Assessment of Cancer Therapy – Gen-
eral (FACT-G). Data were analyzed using descriptive statistics, cor-
relation and regression analyses.
Results: Subjects (N 5 120) were a median of 62 months from
aHSCT (range 34–156), predominantly male (59%), married
(63%), and had an ECOG status of 0 (86%). Mean scores for PS ad-
justment did not differ between the RIC (27.662.56) and MC
(26.161.82) groups (t5 4.93, p5 0.62). Age, gender, marital status,
education, employment, transplant conditioning intensity, perfor-
mance status and physical symptom distress explained 50.5% of
the variability in PAIS scores (F 5 9.30, p\0.01). Being unmarried
(b 520.169, p 5 0.044) and experiencing greater physical symptom
distress (b 5 0.609, p\0.001) independently predicted poor adjust-
ment. Poor PS adjustment was strongly associated with poor
HRQL (r520.78, p\0.001). Survivors (n5 29; 24%) with poor ad-
justment (PAIS T-score $62) reported the greatest difficulties with
family (immediate and extended) issues, sexual relationships and
psychological distress.
Conclusion: Understanding the factors that predict poor PS
adjustment in survivors of aHSCT guides assessment strategies in-
cluding approaches to systematically assess and manage distressing
symptoms. Studies to develop and test educational and counseling
interventions that optimize individual and family functioning,
including sexual relationships, in transplant recipients are
warranted.
Acknowledgment: This research was supported by the
Intramural Research Program of the NIH.TRANSPLANT NURSING ORAL-CLINICAL
79
IMPLICATIONS FOR NURSES AND THE SUPPORTIVE CARE NEEDS FOR
CHILDREN UNDERGOING REDUCED INTENSITY CONDITIONING (RIC)
ALLOGENEIC STEM CELL TRANSPLANTATION (RIC-ALLOSCT)
Barrell, C.1, Dietzen, D.1, Shonfeld, T.1, Pinchefsky, S.1, Satwani, P.2
1Morgan Stanley Children’s Hospital of New York Presbyterian, New
York, NY; 2Columbia University, New York, NY
Allogeneic hematopoietic stem transplant (AlloSCT) is a cura-
tive option for many children with malignant and non-malignant
disorders. However, myeloablative AlloSCTs are associated with
20–40% non-relapse related mortality (NRM) in first 100 days
post AlloSCT (Satwani/Cairo et al, BBMT 2005, PBC 2007).
The morbidity and mortality associated with AlloSCT often resultin an increase in length and complexity of nursing care. However,
RIC-SCT may potentially reduce toxicities and lead to a reduction
in supportive care needs associated with an increase in nursing
care; including reduction of blood products, antibiotics, TPN,
and narcotics. There is limited data on the toxicities of RIC-Al-
loSCT in children and the impact on their nursing needs. We eval-
uated the toxicities and supportive care measures during the
conditioning regimen and 30 days post transplant required in 43
children who underwent a RIC-AlloSCT between January 2004-
March 2008 for either a malignant (n5 23) or non-malignant dis-
ease (n 5 21): Median age 10yrs (0.3- 22yrs), UCB (n 5 17),
MFD (n 5 20), MUD (n 5 6). Average risk patients (n 5 41),
poor risk (n 5 2).
Regimens: Busulfan(6.4–8mg/kg)1Fludarabine(150–180mg/m2)
6 ATG(8mg/m2) (n 5 22); Cyclophospamide(60mg/kg)1Fludara-
bine 1 (150mg/m2) 6 ATG(8mg/m2) (n 5 10); Busulfan (12.8–
16mg/kg)1Fludarabine (150mg/m2)1 Alemtuzumab (54mg/ m2)
(n 5 11). Median time to neutrophil and platelet recovery was
14.5 (8–38) and 32.5 (10–99) days, respectively. Median number of
platelet and PRBC tranfusions was 6(0–32) and 3(0–11), respectively.
The incidence of aGVHD (Gr II-IV) was 33%. One patient had pri-
mary graft failure and the incidence of VOD was zero. Median drop
in estimated CrCL from pre transplant to 30 days post was 40% (0–
68). The median highest grade of mucositis was 1 (0–3) with median
number of days on TPN 0 (0–38) and median number of days requir-
ing a PCA 0 (0–30). The median number of days with fever 3 (0–21)
and the median number of infections per patient 1 (0–2) of which 2
patients required line removal. Three patients required ICU
transfer. Day 100 NRM was 2%.
Conclusions: RIC-AlloSCT is safe, well tolerated, and associated
with significantly lower NRM. We hypothesize RIC will demon-
strate a decrease in nursing time and complexity of care. Therefore,
we are in the process of collecting data on our patients who had
a myeloablative AlloSCT to compare the incidence of various
toxicities and subsequent nursing supportive care needs to our
RIC-AlloSCT experience.80
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Pediatric patients in the pre-school age group can pose
unique challenges for their care team and caregivers when un-
dergoing preparative therapy for transplantation. This is espe-
cially true when total body irradiation (TBI) is included in
the preparative regimen. Typically, TBI in the pre-school pa-
tient involves the use of general anesthesia (GA) to ensure
proper positioning, cooperation, and general patient safety.
TBI treatments at our center are given outpatient in BID frac-
tions, over 4–5 days. A consult with anesthesia is included in the
pre-transplant work-up, and the caregiver is given detailed in-
formation about keeping the child NPO for 4–6 hours, not
only once, but twice daily. As a result, many of these children
need daily IV fluids in our clinic. To address these challenges,
our center implemented a program designed to identify pre-
schoolers as potential candidates to receive their TBI treat-
ments without GA. Initial discussions between the transplant
nurse coordinator and the caregiver provide education regard-
ing TBI. The patient is then scheduled for a consultation
with the pediatric radiation oncologist. Discussion includes
the option for the patient to have a ‘‘practice’’ TBI session.
We have found this session key in identifying children who
could receive TBI without GA. The practice session involves
collaboration of skilled radiation therapy technicians and Child
Life Specialists. Age appropriate techniques are used to help
the patient practice their treatment position. The child is
taught how and why the legs and forehead may be taped to
help hold them steady. Children have the choice of watching
a favorite video, or talking to their caregiver through in inter-
com system. The treatment door is closed for 5–7 minutes, sim-
ulating an actual treatment. If the session is successful, the
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mobilization at home. The children enjoy the ‘‘hands on’’ expe-
rience and the opportunity to show others what they have
learned. Our center has successfully treated 4 children (ages
2.6 years – 4.6 years) over the past 2 years without GA. This
has allowed the children to eat ad lib, minimized their time in
clinic, and improved their overall quality of life. In addition,
it is estimated that $55,000 per patient is saved by treating
without GA. There is scant information in the medical litera-
ture about this approach. We plan to continue to study it’s fea-
sibility over the next 2 years.81
TIME IS MONEY!: COST ANALYSIS OF NURSING SALARY EXPENDITURE
AND TIME SAVINGS BY UTILIZING THE BIOPATCH DRESSING FOR CEN-
TRAL VENOUS CATHETERS ON AN INPATIENT BONE MARROW TRANS-
PLANT UNIT
Cunningham, B., Devine, D., Harvey, K. St. Francis Hospital and Health
Centers, Beech Grove, IN; Indiana Blood and Marrow Transplantation,
Beech Grove, IN
Background: The use of a BIOPATCH Dressing for central ve-
nous catheters (CVC) has proven to reduce catheter-related blood-
stream infections (CRBI) and extended patient stays in the Bone
Marrow Transplant Unit (BMTU), University of Wisconsin Hos-
pital. The use of the BIOPATCH Dressing has decreased the num-
ber of CVC dressing changes performed each week by BMTU
nurses at St. Francis Hospital. Nurses gained additional time to
perform more nursing tasks such as patient education and psycho-
social support for patients. Existing literature offered no informa-
tion about the savings in nursing time and salary expenditure by
utilizing a BIOPATCH Dressing for CVC. This study examined
monetary savings for nursing time and salary expenditure by using
the BIOPATCH Dressing.
Method: A data collection tool was designed to track the date
of each CVC dressing change utilizing the BIOPATCH Dressing
from 3/2007 to 2/2008. Other data collected included the reason
for the dressing change and a CVC exit site skin assessment. A
mean time of 10 minutes required to change a CVC dressing
was calculated using observational data from the skill perfor-
mance of 10 BMTU nurses. Information provided by unit man-
agement disclosed that the mean hourly rate for nursing salary
was $30.00.
Results: Analysis of patient data (N 5 71; 1494 hospital days)
revealed the number of required CVC dressing changes under
the old BMTU Policy (M,W,F) would total 640. By using a BIO-
PATCH Dressing, the number of dressing changes under the
amended Policy (1 day/week) totaled 225 representing
a reduction of 65% or 415 dressing changes. Nursing salary ex-
penditure for 640 CVC dressing changes would total
$3,200.00. Nursing salary expenditure for 225 dressing changes
totaled $1,065.00 representing a 66% reduction and savings of
$2,135.00. Nursing time required to complete 640 dressing
changes was 106.5 hours. Nursing time required to complete
225 dressing changes totaled 35.5 hours representing a 66%
reduction and savings of 71 hours.
Conclusion: Study data validated changes in unit policy regarding
CVC dressing changes. By eliminating 2 dressing changes a week,
nurses gain additional time to address patient needs which has in-
creased job satisfaction. The decrease in nursing salary expenditure
was shown to be significant. More research is needed to determine
if money saved can result in hiring of more nurses or changes in
nurse:patient ratios.82
NURSING CARE OF THE BONE MARROW TRANSPLANT PATIENT WITH
HEMORRHAGIC CYSTITIS
Eron, B., Talbert, G., Shea, T. UNC Hospital, Chapel Hill, NC
Hemorrhagic cystitis is a complication that can occur after an
allogeneic stem cell transplant. Painful bladder spasms, urinary
bleeding, clots and frequency are symptoms that patients oftenpresent with during episodes of hemorrhagic cystitis. Savon
(2007) states that hemorrhagic cystitis is caused by BK virus, a hu-
man polyomavirus acquired in childhood, which remains latent in
the genitourinary tract throughout life. Arthur (1986) noted an as-
sociation between activation of BK virus and hemorrhagic cystitis
in allogeneic stem cell recipients. In an effort to reduce viral load,
weekly infusions of cidofovir are often used until the BK copies
are detected less often, prednisone dose is reduced and immuno-
suppressant therapy is being tapered. Recently in an attempt at
symptom relief, weekly intravesicular (bladder) cidofovir infusions
have been used with some success. The bladder infusions of cido-
fovir are specifically for relief of the discomfort related to the
hemorrhagic cystitis and do not treat the BK virus. Patients’
most frequent complaint associated with hemorrhagic cystitis is
pain. The cidofovir bladder infusion is designed to coat the inside
of the bladder with a dilute solution of cidofovir. This is achieved
by instilling the solution and clamping the bladder for 45 minutes
to one hour. Encouraging the patient to void prior to the instilla-
tion did reduce some discomfort. Each patient’s pain tolerance is
different and determining the appropriate amount of pain medica-
tion to alleviate the discomfort of instilling a foley catheter, med-
ication, clamping, and tolerating the time of the treatment were
all significant challenges. Clearly addressing the challenges of
the procedure and enlisting the patient’s assistance in selecting
the amount and timing of the pain medication gave the patient
some degree of control in a difficult situation. The bladder infu-
sions are routinely preformed on a weekly outpatient basis. Pa-
tients continue until they have an abatement of symptoms;
which has not shown to be related to the number of BK copies
in the urine or serum BK virus. The purpose of this poster is to
describe the unique aspects of nursing care for the BMT patient
receiving intravesicular cidofovir for the management of BK virus
associated cystitis.PHARMACY ORAL
83
IMPACT OF A PHARMACIST IN THE OUTPATIENT ALLOGENEIC STEM
CELL TRANSPLANT CLINIC
Burzynski, J.A.1, Craver, L.F.2, Geerdes, P.A.1, Perreault, S.K.1,
Litzow, M.R.1, Hogan, W.J.1, Elliott, M.A.1, Wolf, R.C.1 1Mayo Clinic,
Rochester, MN; 2Drake University, Des Moines, IA
Background: Although it has demonstrated benefit in cancer
patients, pharmacist involvement in direct patient care of alloge-
neic stem cell transplant (SCT) patients has not been described.
The 2009 National Patient Safety Goals from the Joint Commis-
sion emphasize the importance of accurate and complete medica-
tion lists (including drug, dose, route, and frequency) across the
continuum of care to reduce adverse drug events. We hypothesize
that including a pharmacist in the care of patients undergoing al-
logeneic SCT will improve medication list accuracy and improve
pharmaceutical care.
Methods: Allogeneic SCT patients commenced scheduled phar-
macist appointments at Mayo Clinic on 5/5/08 prior to their physi-
cian visit to complete medication reconciliation and provide
pharmaceutical care. Allogeneic SCT patients were included if
they had a pharmacist appointment in the SCT clinic between 5/5/
08 and 10/1/08. Patients were excluded if they refused consent for
use of their medical records for research or had not been evaluated
by a Mayo Clinic physician for more than 1 year. Retrospective
data was collected to analyze trends in medication list accuracy.
Mean medication list omissions were compared by Wilcoxon rank-
sum tests and McNemar’s test was used to compare error-free med-
ication lists. Pharmaceutical care recommendations and outcomes
(drug interaction management, dose adjustment in organ dysfunc-
tion, formulation changes to improve adherence or efficacy, etc.)
were recorded.
Results: A pharmacist met with 90 patients between 5/5/08 and
10/1/08 prior to each physician visit, totaling 410 patient visits
during 105 clinic days. Three patients were excluded; consent re-
fused (n 5 2) and no physician visit at Mayo Clinic during past
year (n 5 1). Patients had a range of 3 to 49 medications (median
